Disruptive Pharma raises 41 million SEK to develop pipeline project towards clinical stage

We have some exciting news to share just before the summer – Disruptive Pharma just closed a 41 million SEK financing round! We couldn’t be more excited as it allows us to fund continued development of lead pipeline project towards
clinical proof-of-concept. The investment also enables Disruptive Pharma to fund continued development towards identification of a lead candidate and to complete the development of oral grade Pharma MMC. Pharmaceutical grade mesoporous magnesium carbonate, Pharma MMC, is an innovative drug delivery technology for amorphous stabilization and solubility enhancement of drug substances and for unique drug formulations. Much appreciation to our shareholders who continue to support and invest in us! We are also delighted to welcome our new shareholders who believe in our mission.

Also, if you are interested in joining us, keep an eye on our careers page for openings!
#disruptivepharma